Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Junshi’s Novel SARS-CoV-2 Therapy Out-Performs Pfizer’s Paxlovid

publication date: May 25, 2022

Shanghai Junshi Biosciences reported that its novel SARS-CoV-2 therapy reduced recovery time in a Phase III trial compared to Pfizer’s Paxlovid, the current standard of care. According to Junshi, its candidate, VV116, provided a statistically significant improvement in time-to-recovery among patients with mild to moderate COVID-19 who are at high risk for disease progression. VV116 is an oral nucleoside analog drug that inhibits the replication of SARS-CoV-2. It was developed by several China government institutes including the Shanghai Institute of Materia Medica, plus Suzhou Vigonvita Life Sciences and Junshi Bio. More details....

Stock Symbols: (HK: 1877; SHA: 688180)

Share this with colleagues: